Insider Buying: Diurnal Group PLC (DNL) Insider Purchases 10,791 Shares of Stock
Diurnal Group PLC (LON:DNL) insider John Goddard bought 10,791 shares of the business’s stock in a transaction on Thursday, September 7th. The stock was purchased at an average price of GBX 5 ($0.06) per share, for a total transaction of £539.55 ($696.82).
Shares of Diurnal Group PLC (LON DNL) opened at 133.50 on Friday. The firm has a 50-day moving average of GBX 132.00 and a 200 day moving average of GBX 130.18. The firm’s market capitalization is GBX 69.70 million. Diurnal Group PLC has a 12-month low of GBX 105.00 and a 12-month high of GBX 143.50.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/08/insider-buying-diurnal-group-plc-dnl-insider-purchases-10791-shares-of-stock.html.
Several equities research analysts have weighed in on DNL shares. Numis Securities Ltd reiterated a “buy” rating and issued a GBX 169 ($2.18) target price on shares of Diurnal Group PLC in a report on Wednesday. Panmure Gordon reiterated a “buy” rating and issued a GBX 178 ($2.30) target price on shares of Diurnal Group PLC in a report on Thursday, June 15th.
Diurnal Group PLC Company Profile
Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.
Receive News & Ratings for Diurnal Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.